ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP FOR DENMARK PHARMACEUTICALS

Published Jan 5, 2016
Princeton, NJ—January 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. ISPOR Global Health Care Systems Road Maps can benefit a variety of stakeholders—such as health care decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for health care technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific health care experts and are updated over time to reflect changes in the country’s health care delivery system. Denmark flag map According to the newly published ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals, all Danish citizens are covered by national health insurance. The Danish Medicines Agency decides the reimbursement status for pharmaceutical products and is responsible for legislation concerning pharmaceuticals, medical devices, and clinical trials. Marketing authorization in Denmark is regulated according to European Union (EU) regulation by the European Medicines Agency and does not differ in Denmark from that of other European countries. The total public health care expenditure in Denmark for 2014 were 102,569 billion Danish Krone (DKK) and pharmaceutical spending constituted 12.4% of regional health care expenses. The ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals may be found here. Other ISPOR Global Health Care Systems Road Maps published in 2015 include: -          USA – Pharmaceuticals -          Australia – Pharmaceuticals -          Australia – Medical Devices and Diagnostics   Additional information on all of the ISPOR Tools for Health Care Decision Makers may be found here.

###

 

Related Stories

ISPOR Announces New Strategic Plan 2030

Jul 29, 2024

ISPOR announced its new Strategic Plan 2030 that presents a bold new vision for the Society and the field of health economics and outcomes research (HEOR).

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×